Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.315 EUR -1.1% Market Closed
Market Cap: 36.3m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Gensight Biologics SA
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Gensight Biologics SA
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Gensight Biologics SA
PAR:SIGHT
Current Portion of Long-Term Debt
€6.7m
CAGR 3-Years
9%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Current Portion of Long-Term Debt
€22.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Current Portion of Long-Term Debt
€8m
CAGR 3-Years
41%
CAGR 5-Years
13%
CAGR 10-Years
45%
Inventiva SA
PAR:IVA
Current Portion of Long-Term Debt
€5.7m
CAGR 3-Years
N/A
CAGR 5-Years
124%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Current Portion of Long-Term Debt
€15m
CAGR 3-Years
52%
CAGR 5-Years
14%
CAGR 10-Years
36%
OSE Immunotherapeutics SA
PAR:OSE
Current Portion of Long-Term Debt
€3.9m
CAGR 3-Years
75%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

Gensight Biologics SA
Glance View

Market Cap
36.3m EUR
Industry
Biotechnology

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

SIGHT Intrinsic Value
0.171 EUR
Overvaluation 46%
Intrinsic Value
Price

See Also

What is Gensight Biologics SA's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
6.7m EUR

Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Current Portion of Long-Term Debt amounts to 6.7m EUR.

What is Gensight Biologics SA's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
56%

Over the last year, the Current Portion of Long-Term Debt growth was -57%. The average annual Current Portion of Long-Term Debt growth rates for Gensight Biologics SA have been 9% over the past three years , 56% over the past five years .

Back to Top